Free Trial

DexCom (DXCM) Stock Forecast & Price Target

DexCom logo
$81.01 +0.10 (+0.12%)
(As of 06:00 PM ET)

DexCom - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
6
Buy
12

Based on 18 Wall Street analysts who have issued ratings for DexCom in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 18 analysts, 6 have given a hold rating, 11 have given a buy rating, and 1 has given a strong buy rating for DXCM.

Consensus Price Target

$104.59
29.11% Upside
According to the 18 analysts' twelve-month price targets for DexCom, the average price target is $104.59. The highest price target for DXCM is $161.00, while the lowest price target for DXCM is $75.00. The average price target represents a forecasted upside of 29.11% from the current price of $81.01.
Get the Latest News and Ratings for DXCM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for DexCom and its competitors.

Sign Up

DXCM Analyst Ratings Over Time

TypeCurrent Forecast
12/5/23 to 12/4/24
1 Month Ago
11/5/23 to 11/4/24
3 Months Ago
9/6/23 to 9/5/24
1 Year Ago
12/5/22 to 12/5/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$104.59$104.59$112.25$132.33
Forecasted Upside29.11% Upside50.05% Upside62.56% Upside12.91% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

DXCM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DXCM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

DexCom Stock vs. The Competition

TypeDexComMedical CompaniesS&P 500
Consensus Rating Score
2.72
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside27.86% Upside27,283.77% Upside7.49% Upside
News Sentiment Rating
Positive News

See Recent DXCM News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/25/2024Sanford C. Bernstein
3 of 5 stars
 Boost TargetOutperform ➝ Outperform$82.00 ➝ $86.00+16.55%
10/25/2024Royal Bank of Canada
4 of 5 stars
 Lower TargetOutperform ➝ Outperform$120.00 ➝ $115.00+53.54%
10/25/2024Raymond James
4 of 5 stars
 Lower TargetStrong-Buy ➝ Strong-Buy$115.00 ➝ $99.00+32.18%
10/25/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$115.00 ➝ $105.00+39.55%
10/25/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$75.00 ➝ $85.00+15.66%
10/25/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$90.00 ➝ $87.00+19.10%
10/25/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$80.00 ➝ $90.00+20.24%
8/26/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00+20.74%
8/23/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$90.00 ➝ $100.00+38.35%
8/5/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$80.00 ➝ $82.00+13.42%
7/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$138.00 ➝ $113.00+67.33%
7/26/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Johnson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/26/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$156.00 ➝ $120.00+88.62%
7/26/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$120.00 ➝ $75.00+19.73%
7/26/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$163.00 ➝ $95.00+49.42%
7/23/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$145.00 ➝ $145.00+29.87%
5/30/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$130.00+1.85%
4/3/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$148.00 ➝ $161.00+15.86%
10/16/2023Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Kratky
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/10/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$114.00 ➝ $125.00+16.56%
1/26/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$121.00+16.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:35 PM ET.


Should I Buy DexCom Stock? DXCM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, November 25, 2024. Please send any questions or comments about these DexCom pros and cons to contact@marketbeat.com.

DexCom
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in DexCom, Inc.:

  • Recent analyst upgrades have increased target prices, with Sanford C. Bernstein raising their target from $82.00 to $86.00, indicating positive market sentiment and potential for stock appreciation.
  • The current stock price is $75.88, which is significantly lower than its fifty-two week high of $142.00, suggesting a potential buying opportunity for investors looking for value.
  • DexCom, Inc. has a strong market capitalization of $29.64 billion, reflecting its solid position in the medical device industry, particularly in continuous glucose monitoring systems.
  • The company has a healthy current ratio of 2.46, indicating that it has more than enough assets to cover its short-term liabilities, which is a positive sign for financial stability.
  • With a P/E ratio of 45.44, while high, it reflects investor confidence in the company's growth potential, especially in the expanding diabetes management market.

DexCom
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in DexCom, Inc. for these reasons:

  • Recent downgrades from brokerages, such as StockNews.com reducing their rating from "buy" to "hold," suggest that some analysts are cautious about the stock's near-term performance.
  • The stock has experienced a significant decline from its fifty-two week high of $142.00, which may indicate underlying issues or market volatility that could affect future performance.
  • With a P/E/G ratio of 2.33, the stock may be considered overvalued relative to its growth rate, which could deter value-focused investors.
  • Insider ownership is relatively low at 0.30%, which may raise concerns about the alignment of management's interests with those of shareholders.
  • The company has a debt-to-equity ratio of 1.23, indicating that it has a higher level of debt compared to equity, which could pose risks if market conditions change.

DXCM Forecast - Frequently Asked Questions

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for DexCom is $104.59, with a high forecast of $161.00 and a low forecast of $75.00.

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 6 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares.

According to analysts, DexCom's stock has a predicted upside of 29.11% based on their 12-month stock forecasts.

DexCom has been rated by research analysts at JPMorgan Chase & Co., Leerink Partners, Oppenheimer, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, and Wells Fargo & Company in the past 90 days.

Analysts like DexCom less than other "medical" companies. The consensus rating score for DexCom is 2.72 while the average consensus rating score for "medical" companies is 2.80. Learn more on how DXCM compares to other companies.


This page (NASDAQ:DXCM) was last updated on 12/4/2024 by MarketBeat.com Staff
From Our Partners